Inter-rater variability for the American Society of Anesthesiologists classification in patients undergoing hepato-pancreato-biliary surgery (MILESTONE-2): international survey among surgeons and anaesthesiologists
Simone Augustinus(Amsterdam University Medical Centers), Marc G. Besselink, Tobias Keck(Krankenhaus der Augustinerinnen), Giuseppe Natalini(Fondazione Poliambulanza Istituto Ospedaliero), Luca Aldrighetti(Vita-Salute San Raffaele University), Mohammad Abu Hilal(Fondazione Poliambulanza Istituto Ospedaliero), Jasper P. Sijberden(HealthNet TPO), Bas Groot Koerkamp, Thomas Kander(Lund University), John A. Windsor(University of Auckland), Martin H. Smith(University of the Witwatersrand), Giuseppe Fusai(The Royal Free Hospital), Francisco Carlos Bonofiglio(Hospital Italiano de Buenos Aires), Shailesh V. Shrikhande(Homi Bhabha National Institute), Adnan Alseidi(Virginia Mason Medical Center), Carla Nau, Bobby Tingstedt(Lund University), Michael Guertin(The Ohio State University Wexner Medical Center), Joris I. Erdmann(Amsterdam University Medical Centers), Eduardo de Santibáñes(Universidad de Buenos Aires), Attila Szíjártó(Semmelweis University), Timothy M. Pawlik(Johns Hopkins University), Markus W. Hollmann(Amsterdam University Medical Centers), Dominik Krzanicki(The Royal Free Hospital), Katia Donadello(Université Libre de Bruxelles), Kevin C. Conlon(Trinity College Dublin), Ronald L. Harter(The Ohio State University Wexner Medical Center), Matthanja Bieze(University of Toronto), Manuel Pardo(University of California, San Francisco), Roberto Salvia(Pancreas Centre (Canada)), Vandana Agarwal(Homi Bhabha National Institute), Maria Elena Franceschetti(Fondazione Poliambulanza Istituto Ospedaliero), Ho‐Jin Lee(Seoul National University Hospital), Cristina R. Ferrone(Brigham and Women's Hospital), Keith E. Lewis(Rutgers, The State University of New Jersey), Jin‐Young Jang(Seoul National University), Alice C. Wei(Université Paris Cité), Henry A. Pitt(Barnes-Jewish Hospital), Thilo Hackert(University Hospital Heidelberg)
Cited by 7
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
|Science|2017|1.8k
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
|Clinical Cancer Research|2013|938
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914